Immatics N.V. (NASDAQ:IMTX) Given Average Rating of “Moderate Buy” by Analysts

Shares of Immatics N.V. (NASDAQ:IMTX) have been assigned a consensus rating of “Moderate Buy” from the nine research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $19.00.

Several research analysts have weighed in on IMTX shares. Chardan Capital reaffirmed a “buy” rating and issued a $25.00 target price on shares of Immatics in a research report on Monday, November 24th. Mizuho set a $25.00 price target on Immatics in a report on Thursday, February 19th. Jefferies Financial Group started coverage on Immatics in a report on Monday, March 16th. They issued a “buy” rating and a $18.00 price objective on the stock. Wall Street Zen raised shares of Immatics from a “sell” rating to a “hold” rating in a research report on Monday, March 9th. Finally, Leerink Partners reiterated an “outperform” rating and issued a $17.00 target price on shares of Immatics in a research note on Thursday, December 4th.

Immatics Stock Up 0.8%

Immatics stock opened at $9.51 on Tuesday. The company’s fifty day simple moving average is $9.86 and its 200-day simple moving average is $9.55. Immatics has a 12 month low of $3.30 and a 12 month high of $12.41. The stock has a market cap of $1.28 billion, a P/E ratio of -5.17 and a beta of 1.34.

Immatics (NASDAQ:IMTX) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.14. The business had revenue of $23.00 million for the quarter, compared to the consensus estimate of $12.18 million. Immatics had a negative net margin of 411.90% and a negative return on equity of 41.81%. On average, equities research analysts expect that Immatics will post -0.72 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Jefferies Financial Group Inc. boosted its holdings in Immatics by 323.4% in the fourth quarter. Jefferies Financial Group Inc. now owns 5,059,551 shares of the company’s stock worth $53,125,000 after purchasing an additional 3,864,636 shares in the last quarter. RTW Investments LP raised its holdings in Immatics by 29.7% during the fourth quarter. RTW Investments LP now owns 11,433,354 shares of the company’s stock valued at $120,050,000 after buying an additional 2,617,737 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in Immatics by 10.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 21,459,156 shares of the company’s stock valued at $225,322,000 after buying an additional 2,075,987 shares in the last quarter. Baker BROS. Advisors LP lifted its position in shares of Immatics by 18.9% in the third quarter. Baker BROS. Advisors LP now owns 12,094,094 shares of the company’s stock worth $103,042,000 after buying an additional 1,925,193 shares during the last quarter. Finally, Sofinnova Investments Inc. lifted its position in shares of Immatics by 54.2% in the fourth quarter. Sofinnova Investments Inc. now owns 3,435,542 shares of the company’s stock worth $36,073,000 after buying an additional 1,207,705 shares during the last quarter. Institutional investors own 64.41% of the company’s stock.

About Immatics

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.